Luteolin as a dietary flavonoid for brain health: modulating neuroinflammation and cognitive decline in neurodegenerative disorders.
This review compiles preclinical and limited clinical evidence that luteolin, a dietary flavonoid, can reduce neuroinflammation, oxidative stress, and pathological protein aggregation (including α-synuclein) and improve cognitive and motor outcomes in models of neurodegeneration, but its…
What the AI sees
This review compiles preclinical and limited clinical evidence that luteolin, a dietary flavonoid, can reduce neuroinflammation, oxidative stress, and pathological protein aggregation (including α-synuclein) and improve cognitive and motor outcomes in models of neurodegeneration, but its…
Research significance
It identifies actionable, PD-relevant mechanisms (NF-κB/MAPK anti-inflammatory effects, Nrf2 antioxidant activation, BDNF-related synaptic support, and mitigation of α-synuclein aggregation) that support luteolin as a repurposing/formulation target for neuroprotective strategies in Parkinson's…
Source abstract
Luteolin, a flavonoid naturally present in a variety of fruits, vegetables, and medicinal plants, has been recognized as a potentially effective neuroprotective nutraceutical because of its remarkable anti-inflammatory, antioxidant, and neurotrophic properties. Increasing evidence suggests that neuroinflammation and oxidative stress are major contributors to cognitive decline and neuronal degeneration in several prominent neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and multiple sclerosis (MS). Luteolin significantly inhibits microglial activation, reduces pro-inflammatory cytokine production, modulates the nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways, and enhances Nrf2-mediated antioxidant mechanisms. Furthermore, it promotes synaptic plasticity through brain-derived neurotrophic factor (BDNF)-associated pathways and mitigates the aggregation of pathological proteins, including Aβ, tau, α-synuclein, and mutant huntingtin. Preclinical studies consistently demonstrate substantial improvements in cognitive function, motor performance, demyelination, and neuronal viability in models of AD, PD, MS, and HD. Preliminary clinical observations also indicate prospective advantages for cognitive function, regulation of inflammatory responses, and alleviation of symptoms, particularly concerning AD and MS. Notwithstanding these encouraging outcomes, obstacles persist due to luteolin's restricted bioavailability, ideal dosing parameters, and the translational discrepancies between experimental models and human pathophysiological conditions. In summary, luteolin emerges as a noteworthy candidate for nutraceutical-oriented approaches designed to alleviate neuroinflammation and cognitive deterioration in the context of neurodegenerative diseases.